pPACK-SPIKE B.1.351 S1 Mutations, SARS-CoV-2 S Pseudotype - B.1.351 (S. African) Variant - S1 Mutations (RBD+D614G) - Lentivector Packaging Mix

Product Description

Safely study the spike protein from emerging SARS-CoV-2 variants

• Based on SBI’s popular and highly cited pPACKH1 Packaging System
• Uses codon-optimized SARS-CoV-2 K417N, E484K, N501Y, D614G "S" protein in place of VSV-G envelope protein
• Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
• Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
• Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
• Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

As potentially more transmissible variants of SARS-CoV-2 emerge, understanding how mutations in the spike protein impact SARS-CoV-2 behavior is critical. With the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the emerging South African lineage B.1.351 (also known as 501Y.V2)-K417N, E484K, N501Y, and D614G. Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 K417N, E484K, N501Y, D614G spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.

Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 K417N, E484K, N501Y, D614G Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, K417N, E484K, N501Y, D614G "Spike" pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.

pPACK-SPIKE B.1.351 S1 Mutations (RBD + D614G) Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as the pPACK-SPIKE B.1.351 S1 Mutations Combo Kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

How It Works

pPACK-SPIKE is easy to use - simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Available pPACK-SPIKE S protein variants